Cortice Biosciences, Inc. (Cortice)

Oncology Corporate Profile

HQ Location

50 W 57th Street, 15th Floor
New York, NY 10019

Company Description

Cortice Biosciences is advancing the development of a novel class of taxoids, known as abeotaxanes, for potential treatment of a wide range of cancers and neurologic disorders. The company's lead product candidate, TPI 287, has a number of advantages over existing taxane drugs, such as paclitaxel (Taxol® and Abraxane®) and docetaxel (Taxotere®), including the ability to penetrate the blood-brain barrier. This unique property enables the potential treatment of primary brain tumors and other cancers that spread to the brain, as well as non-cancer related diseases of the central nervous system.

Website: http://www.corticebio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TPI-287taxoid derivativeBrain MetastasesII
TPI-287taxoid derivativeGlioblastoma Multiforme (GBM)II
TPI-287taxoid derivativeNeuroblastomaII
TPI-287 (+ radiotherapy)taxoid derivativeBrain MetastasesI

Source: http://www.corticebio.com

Recent News Headlines

There are no news items to display